POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies
Por:
McMillan, AK, Matasar, MJ, Sancho, JM, Viardot, A, Hernandez, J, Perretti, T and Haioun, C
Publicada:
13 nov 2019
Resumen:
Filiaciones:
McMillan, AK:
Nottingham Univ Hosp NHS Trust, Ctr Clin Haematol, Nottingham, England
Matasar, MJ:
Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA
:
HU Germans Trias & Pujol, Barcelona, Spain
Viardot, A:
Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
Hernandez, J:
F Hoffmann La Roche Ltd, Basel, Switzerland
Perretti, T:
F Hoffmann La Roche Ltd, Basel, Switzerland
Haioun, C:
Grp Hosp Henri Mondor, Lymphoid Malignancies Unit, Creteil, France
|